


RECEIVED

OCT 28 2002

TECH CENTER 1600/2900



I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service as first class mail in a box addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231,

On March 25, 2002

Quine Intellectual Property Law Group, P.C.

By Tracie Brooks  
Tracie Brooks

Attorney-Docket No. 02-030210US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen, *et al.*

Application No.: 09/247,886

Filed: February 10, 1999

For: TARGETING OF GENETIC  
VACCINE VECTORS

Examiner: S. Chen

Art Unit: 1633

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the  
attention of the Examiner. Copies of the references are enclosed. It is respectfully requested  
that the cited information be expressly considered during the prosecution of this application,  
and the references be made of record therein and appear among the "references cited" on any  
patent to issue therefrom.

**COPY**

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action.

Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

*This paper is submitted in duplicate.*

Respectfully submitted,



Jonathan A. Quine  
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. Box 458  
Alameda, CA 94501  
Tel: (510) 337-7871  
Fax: (510) 337-7877

**COPY**



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031


<b>Substitution Form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	09/247,886
	Filing Date	February 10, 1999
	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,252,714		Harris et al.	10-12-1993	
	2	5,348,867		Georgiou et al.	09-20-1994	
	3	5,512,463		Georgiou et al.	09-20-1994	
	4	5,514,588		Varadaraj	05-07-1996	
	5	5,571,698		Ladner et al.	11-05-1996	
	6	5,691,170		Gritz et al.	11-25-1997	
	7	5,763,239		Short et al.	06-09-1998	
	8	5,789,228		Lam et al.	08-04-1998	
	9	5,814,473		Warren et al.	09-29-1998	
	10	5,862,514		Kauffman et al.	10-20-1998	
	11	5,866,344		Georgiou	02-02-1999	
	12	5,876,997		Kretz	03-02-1999	
	13	5,882,883		Egel-Mitani et al.	03-16-1999	
	14	5,925,749		Mathur, et al.	07-20-1999	
	15	5,939,300		Robertson, et al.	08-17-1999	
	16	5,942,430		Robertson, et al.	08-24-1999	
	17	5,948,666		Callen, et al.	09-07-1999	
	18	5,958,751		Murphy, et al.	09-28-1999	
	19	5,962,258		Mathur, et al.	10-05-1999	
	20	5,962,283		Warren et al.	10-05-1999	
	21	5,985,285		Titball et al.	11-16-1999	
	22	5,985,646		Murphy, et al.	11-16-1999	
	23	6,043,030		Beach et al.	03-28-2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**COPY**



Substitute for PTO Form 08A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

	24	6,054,312		Lacocca et al.	04-25-2000	
	25	6,087,341		Khavari et al.	07-11-2000	
	26	6,153,410		Arnold et al.	11-28-2000	
	27	6,156,511		Schatz et al.	12-05-2000	
	28	6,159,687		Vind	12-12-2000	
	29	6,159,688		Borchert et al.	12-12-2000	
	30	6,165,718		Borchert et al.	12-26-2000	
	31	6,165,793		Stemmer	12-26-2000	
	32	6,168,919		Short	01-02-2001	
	33	6,171,820		Short	01-09-2001	
	34	6,174,673		Short et al.	01-16-2001	
	35	6,177,263		Arnold et al.	01-23-2001	
	36	6,180,406		Stemmer et al.	01-30-2001	
	37	6,194,183		Markvardsen et al.	02-27-2001	
	38	6,238,884		Short et al.	05-29-2001	
	39	6,251,674		Tobin et al.	06-26-2001	
	40	6,261,561		Stewart, Jr. et al.	07-17-2001	
	41	6,287,861		Stemmer et al.	09-11-2001	

43

FOREIGN PATENT DOCUMENTS								
Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	42	EP	0 125 228	A1	President and Fellows of Harvard College	06-15-1988		

44

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

	43	EP	0 725081	A1	Kyowa Hakko Kogyo Co., Ltd.	08-07-1996		
	44	EP	0876509	B1	Maxygen, Inc.	09-19-2001		
	45	EP	0911396	A2	Stemmer	04-28-1999		
	46	EP	0911396	A3	Stemmer et al.	05-06-1999		
	47	EP	0934999	A1	Stemmer et al.	08-11-1999		
	48	WO	90/14443		Huse	11-29-1990		
	49	WO	91/07979		Center for Innovative Technology	06-13-1991		
	50	WO	92/03461		Ixsys, Inc.	03-05-1992		
	51	WO	92/06204		Ixsys, Inc.	04-16-1992		
	52	WO	92/11272		Ixsys, Inc	07-09-1992		
	53	WO	93/06214		The United States of America	04-01-1993		
	54	WO	93/10214		Georgiou	05-27-1993		
	55	WO	94/06421		The University of Tennessee Research	03-31-1994		
	56	WO	94/23738	A1	Medisorb Technologies International L.P.	10-27-1994		
	57	WO	94/26787	A1	The Boead of Trustees of the Leland Stanford Junior University	11-24-1994		
	58	WO	95/16027	A1	Borrebaeck	06-15-1995		
	59	WO	96/11279	A1	US Department of Health and Human Services	04-18-1996		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

60	WO	96/13250	A1	Amgem, Inc.	05-09-1996		
61	WO	96/37624		MG-PMC, L.L.C.	11-28-1996		
62	WO	97/04077		Recombinant Biocatalysis, Inc.	02-06-1997		
63	WO	97/07128	A1	Duke University	02-27-1997		
64	WO	97/07205		Okkels	02-27-1997		
65	WO	97/11605	A1	University of Pittsburg of the Commonwealth System of Higher Education	04-03-1997		
66	WO	97/25410		Borchert et al	07-17-1997		
67	WO	97/32987	A1	University of Toronto	09-12-1997		
68	WO	97/44361		Lam et al.	11-27-1997		
69	WO	97/48416		Mathur et al.	12-24-1997		
70	WO	97/48717		Short et al.	12-24-1997		
71	WO	97/48794		Murphy et al.	12-24-1997		
72	WO	98/00526		Robertson et al.	01-08-1998		
73	WO	98/01581		Short	01-15-1998		
74	WO	98/05764		Novo Nordisk	02-12-1998		
75	WO	98/05765		Novo Nordisk	02-12-1998		
76	WO	98/24799		Bylina	06-11-1998		
77	WO	98/28416		Bjornvad et al.	07-02-1998		
78	WO	98/36080		Affholter et al.	08-20-1998		
79	WO	98/41622		Borchert et al.	09-24-1998		
80	WO	98/41623		Borchert et al.	09-24-1998		
81	WO	98/41653		Vind et al.	09-24-1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<p>Substitute for form 149A-B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

	82	WO	98/42727		SRI International	10-01-1998		
	83	WO	98/42832		Arnold et al.	10-01-1998		
	84	WO	98/45444		The Regents of the University of California	10-15-1998		
	85	WO	98/48034		Neiboer et al.	10-29-1998		
	86	WO	98/49286		Board of Regents, The University of Texas System	11-05-1998		
	87	WO	98/58085		Short et al.	12-23-1998		
	88	WO	99/07837		Callen	02-18-1999		
	89	WO	99/08539		Kretz	02-25-1999		
	90	WO	99/10472		Short	03-04-1999		
	91	WO	99/10539		Short	03-04-1999		
	92	WO	99/19506		Ixsys, Inc.	04-22-1999		
	93	WO	99/19518		Short	04-22-1999		
	94	WO	99/21979		Apt et al.	05-06-1999		
	95	WO	99/23107		Stemmer et al.	05-14-1999		
	96	WO	99/23236		Diversa Corp. et al.	05-14-1999		
	97	WO	99/29902		Arnold et al.	06-17-1999		
	98	WO	99/41366		The Board of Trustees of the Leland Stanford Junior University	08-19-1999		
	99	WO	99/41368		Maxygen, Inc.	08-19-1999		
	100	WO	99/41369		Maxygen, Inc.	08-19-1999		
	101	WO	99/41383		Maxygen, Inc.	08-19-1999		
	102	WO	99/41402		Maxygen, Inc.	08-19-1999		
Examiner Signature						Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>


	103	WO	99/45154		Short et al.	09-10-1999		
	104	WO	99/57128		Stemmer et al.	11-11-1999		
	105	WO	99/65927		Maxygen, Inc,	12-23-1999		
	106	WO	00/16984		Polard Corporation	03-30-2000		
	107	WO	00/18778		Phylos, Inc.	04-06-2000		
	108	WO	00/42560		Selifonov et al.	07-20-2000		
	109	WO	00/42561		Crameri et al.	07-20-2000		
	110	WO	00/46344		Diversa Corporation	08-10-2000		
	111	WO	00/53744		Short et al.	09-14-2000		
	112	WO	00/58517		Short et al.	10-05-2000		
	113	WO	01/00234		Maxygen, Inc	01-04-2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exami ner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	114	<b>Affholter et al. (1998) "Directed evolution of proteins and pathways by DNA shuffling." Book of Adstracts, 216th ACS National Meeting, Boston, August 23-27, BIOT-042</b>		
	115	<b>Agren et al. (1997) "Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit." <i>J. Immunol</i> 158:3936</b>		
	116	<b>Ahmed (1995) <i>J Bacteriology</i> 177(14):3904-3910</b>		
	117	<b>Ahn et al. (1996) "Human cytomegalovirus inhibits antigen presentation by a sequential multistep process." <i>Proc. Natl. Acad. Sci USA</i> 93:10990</b>		
	118	<b>Aizaki et al. (1998) "Full-Length Complementary DNA of Hepatitis C Virus Genome From an Infectious Blood Sample." <i>Hepatology</i> 27:621-627 (1998)</b>		
	119	<b>Aldovini &amp; Young (1991) "Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines." <i>Nature</i> 351:479-482</b>		
	120	<b>Ambrivovic, A. et al. (1997) "Efficacy of Replication-Defective Adenovirus-Vectored Vaccines: Protection Following Intramuscular Injection Is Linked to Promoter Efficiency in Muscle Representative Cells" <i>Virology</i> 238:, 327-335</b>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.






Substitute for form 449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

121	<b>Appel and Harris</b> (1998) "Antibody titers in domestic ferret kits and kits to canine distemper virus vaccines." <i>JAVMA</i> 193:332-333	
122	<b>Atkins et al.</b> (1996) "Manipulation of the Semliki Forest Virus Genome and Its Potential for Vaccine Construction." <i>Mol Biotechnol</i> 5:33-38	
123	<b>Axon</b> (1998) "Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives." <i>Gut</i> 43(1):S70-3	
124	<b>Baba et al.</b> , "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," <i>The J. of Biolog. Chem.</i> 272 (23): 14893-14898 (1997).	
125	<b>Bass et al.</b> (1990) "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties." <i>Proteins: Structures, Function and Genetics</i> 8:309-314	
126	<b>Beck et al.</b> , "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," <i>J. Mol. Biol.</i> 228:433-441 (1992)	
127	<b>Behrens et al.</b> (1996) "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." <i>EMBO J.</i> 15:12-22	
128	<b>Benham et al.</b> (1997) "Proteasome activity limits the assembly of HMC class 1 molecules after IFN-gamma stimulation." <i>J. Immunol</i> 159(2):5896-5904	
129	<b>Berkhout et al.</b> (1999) "Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains." <i>J. Virology</i> 73(2):1138-1145	
130	<b>Bernard et al.</b> (1994) "Transcriptional Control and Cell Type Specificity of HPV Gene Expression." <i>Arch Dermatol</i> 130:210	
131	<b>Bhatnagar et al.</b> (1982) "Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant." <i>Proc Nat'l Acad Sci USA</i> 79:4400-4404	
132	<b>Bielefeldt-Olmann, H. et al.</b> , "Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system," <i>J. Gen. Virol.</i> 78:2723-2733 (1997)	
133	<b>Blachere et al.</b> , "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity," <i>J. Exp. Med.</i> 186:1315-22 (1997)	
134	<b>Blanchard et al.</b> (1998) "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins. . ." <i>J. Gen. Virol</i> 79:1159-1167	
135	<b>Blaser</b> (1998) "Helicobacter pylori and gastric disease." <i>BMJ</i> 316:1507-1510	
136	<b>Bloom et al.</b> (1993) Characterization of Chimeric Full-Length Molecular Clones of Aleutian Mink Disease Parvovirus (ADV) . . ." <i>J. Virol</i> 67(10):5976-5988	
137	<b>Bolhuis</b> (1995) <i>J. Biological Chemistry</i> 270(3):26092-26098	
138	<b>Botstein and Shortle</b> , "Strategies and Applications of in Vitro Mutagenesis," <i>Science</i> 229:1193-1201 (1985)	
139	<b>Boursnell et al.</b> (1997) "A Genetically Inactivated Herpes Simplex Virus Type 2 (Hsv-2) Vaccine Provides Effective Protection against Primary & Recurrent HSV-2 Disease." <i>J. Infect. Dis</i> 175:16-25	
140	<b>Bray et al.</b> (1989) "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengus Virus Encephalitis." <i>J. Virol</i> 63:2853-2856	
141	<b>Bridgen and Elliot</b> (1996) "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNA's." <i>Proc. Nat'l Acad. Sci USA</i> 93:15400-15404	
142	<b>Brocke et al.</b> (1996) "Treatment of experimental encephalomyelitis with a peptide analogue of myelin	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




<b>Substitute for form PTO/A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

	basic protein." <i>Nature</i> 379:343-346	
143	<b>Brubaker</b> (1991) "The V Antigen of Yersiniae: An Overview." <i>Current Investigations of the Microbiology of Yersiniae</i> 12:127-133	
144	<b>Burger et al.</b> (1995) <i>Proc. of the Amer Assoc. for Cancer Research</i> 36:522 Abst #3108	
145	<b>Burke et al.</b> (1999) "Formulation, Stability and Delivery of Live Attenuated Vaccines for Human Use." <i>Crit. Rev. Ther Drug. Carrier Syst</i> 16:1-83	
146	<b>Burton</b> (1995) "Phage Display." <i>Immunotechnology</i> 1(2):87-94	
147	<b>Carroll and Moss</b> (1997) "Host range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus. . ." <i>Virology</i> 238:198-211	
148	<b>Carter et al.</b> , "Improved oligonucleotide site-directed mutagenesis using M13 vectors," <i>Nucl. Acids Res.</i> 13:4431-4443 (1985)	
149	<b>Carter</b> , "Improved Oligonucleotide-Directed Mutagenesis Using M13 Vectors," <i>Methods in Enzymol.</i> 154:382-403 (1987)	
150	<b>Carter</b> , "Site-directed mutagenesis," <i>Biochem. J.</i> 237:1-7 (1986)	
151	<b>Casal</b> (1999) "Use of parvovirus-like particles for vaccination and induction of multiple immune response." <i>Biotechnol Appl. Biochem</i> 29:-141-150	
152	<b>Cathomen et al.</b> (1998) "A matrix-less measles virus is infectious and extensive cell fusion: consequences for propagation in the brain." <i>EMBO J.</i> 17(14):3899-3908	
153	<b>Chang, C., et al.</b> (1999) "Evolution of a cytokine using DNA family shuffling." <i>Nature Biotechnology</i> 17:793-797.	
154	<b>Chen et al.</b> "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis." <i>Science</i> 265:1237-1240	
155	<b>Chen et al.</b> , "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phase peptide library," <i>Proc. Nat'l. Acad. Sci. USA</i> 93:1997-2001 (1996)	
156	<b>Chin et al.</b> (1993) "Functions and Regulation of the Human Multidrug Resistance Gene." <i>Adv. Cancer Res.</i> 60:157-180	
157	<b>Chu et al.</b> (1995) "A Vaccinia Virus-Vectored Hantaan Virus Vaccinating Protects Hamsters from Challenge with Hantaan and Seoul Viruses but Not Puumala Virus." <i>J. Virol</i> 69:6417	
158	<b>Clackson et al.</b> (1994) "In vitro selection from protein and peptide libraries." <i>Trends Biotechnol</i> 12(5): 173-184	
159	<b>Coco et al., (2001)</b> "DNA shuffling method for generating highly recombined genes and evolved enzymes" <i>Nature Biotechnology</i> vol. 19 pp. 354-359	
160	<b>Collman et al.</b> (1992) "An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1." <i>J. Virol</i> 66(12):7517-7521	
161	<b>Conry et al.</b> (1996) "Selected strategies to augment polynucleotide immunization." <i>Gene Therapy</i> 3(1):67-74	
162	<b>Cote et al.</b> (1986) "Protection of Chimpanzees from Type B Hepatitis by Immunization with Woodchuck Hepatitis Virus Surface Antigen." <i>J. Virol</i> 60:895-901	
163	<b>Crabtree</b> (1998) "Eradication of chronic Helicobacter pylori infection by therapeutic vaccination." <i>Gut</i> 43:7-8	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

164	Craiu et al., "Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide," <i>Proc. Nat'l. Acad. Sci. USA</i> 94:10850-10855 (1997)	
165	Cramer & Stemmer (1993) "10(20)-fold aptamer library amplification without gel purification." <i>Nucleic Acids Research</i> 21(18): 4410	
166	Cresswell & Hughes, "Protein degradation: The ins and outs of of the matter," <i>Curr. Biol.</i> 7:R552-R555x (1997)	
167	Cwirla et al. (1990) "Peptides on Phage: A vast library of peptides for identifying ligands." <i>Proc. Nat'l Acad Sci USA</i> 87:6378-6382	
168	Davis et al (1995) "DNA-based immunization." <i>Molecular and Cell Biology of Human Gene Therapeutics</i> 5:368-387	
169	Davis et al. (1989) "In vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant." <i>Virology</i> 171:189-204	
170	Davis et al. (1997) "DNA-Baised immunization against hepatitis B surface antigen (HBsAg) in Normal and HBsAg-transgenic mice." <i>Vaccine</i> 15(8) 849-822	
171	Devlin et al. (1990) "Random Peptide Libraries: A Source of Specific Protein Binding Molecules." <i>Science</i> 249:404-406	
172	Dieu et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," <i>J. Exp. Med.</i> 188:373-386 (1998)	
173	DiMarco et al. (1997) "Agnostic and antagonistic variants of ciliary neurotrophic Factor (CNTF) Reveal functional differences between mambrean-bound and soluble CNTF Alpha-receptors." <i>J Biol. Chem.</i> 272(37):23069-23075	
174	Donovan et al. (1987) "Genes Encoding Spore Coat Polypeptides from Bacillus subtilis." <i>J. Mol Biol</i> 196:1-10	
175	Drabkin et al. (1996) "Amber Suppression in Mammalian Cells Dependent upon Expression of an Escherichia coli Aminoacyl-tRNA Synthetase Gene." <i>Mol Cell. Biol.</i> 16(3):907-913	
176	Dubois et al. (1998) "Immunization against Natural Helicobacter pylori Infection in Nonhuman Primates." <i>Infect. Immun.</i> 66:4340-4346	
177	Dunn (1996) "Phage display of proteins." <i>Curr Opin Biotechnology</i> 7(5):547-553	
178	Eghtedarzadeh and Henikoff, "Use of oligonucleotides to generate large deletions," <i>Nucl. Acids Res.</i> 14:5115 (1986)	
179	Engels and Ackermann (1996) "Pathogenesis of ruminant herpesvirus infections." <i>Vet Microbiol</i> 53:3-15	
180	Felici, Franco et al., "Peptide and protein display on the surface of filamentous bacteriophage," <i>Biotechnol. Annu. Rev.</i> 1:149-83 (1995)	
181	Fields et al., "Crystal structure of a T-cell receptor B-chain complexed with a superantigen," <i>Nature</i> 384:188-192 (1996)	
182	Francisco, Joseph A. et al., "Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface," <i>Proc. Nat'l. Acad. Sci. USA</i> 90:10444-10448 (1993)	
183	Frankel and Young (1998) "HIV-1 Fifteen Proteins and an RNA." <i>Annu. Rev. Biochem</i> 67:1-25	
184	Freeman et al., "B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

	Preferentially Costimulates the Initial Production of IL-4," Immunity 2:523 (1995)	
185	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)	
186	Gaczynska et al., "Proteasome Subunits X and Y alter Peptidase Activities in Opposite Ways to the Interferon- $\gamma$ -induced Subunits LMP2 and LMP7," J. Biol. Chem. 271:17275-17280 (1996)	
187	Galler et al. (1997) "The Yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector." J. Med Biol. Res. 30:157-168	
188	Galocha et al. (1997) "The Active Site of ICP47, a Herpes Simple Virus-encoded Inhibitor of the Major Histocompatibility Complex. . ." J. Exp. Med 185:1565-1572	
189	Garnett and Grenfell (1992) "The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster." Epidemiol. Infect 108:513-528	
190	Geigenmuller et al. (1997) "Construction of a Genome-Length cDNA Clone for Human Astrovirus Serotype 1 and Synthesis of Infectious RNA Transcripts." J. Virol 71:1713-1717	
191	Goldman et al. (1999) Molecular Cloning and Expression of Major Structural Protein. . ." J. Virol. 73:4465-4469	
192	Gritsun et al. (1998) "Development and analysis of a tick-borne encephalitis virus infectious clone using a novel and rapid strategy." J Virol. Methods 76:109-120	
193	Groettrup et al. "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome," Proc. Nat'l. Acad. Sci. USA 94:8970-8975 (1997)	
194	Groettrup et al., "A third interferon - $\gamma$ -induced subunit exchange in the 20S proteasome," Eur. J. Immunol. 26:863-869 (1997)	
195	Groux et al., "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature 389:737 (1997)	
196	Grundstrom et al., "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis," Nucleic Acids Res. 13:3305-3316 (1985)	
197	Gualano et al. (1998) "Identification of a major determinant of mouse neurovirulence of dengue virus typw 2 using stably cloned genomic-length cDNA." J. Gen. Virol. 79:437-466	
198	Guo et al. (1998) "Susceptibility to recombination rearrangements of a chimeric plum pox potyvirus genome after insertion of a foreign gene." Virus Res 57:183-195	
199	Halminen et al. (1997) "Expression of MXA Protein in Blood Lymphocytes Discriminates between Viral and Bacterial Infections in Febrile Children." Pediatric Research 41:647-650	
200	Han, Xiaoliang et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci USA 92:9747-9751 (1995)	
201	Hanes, Jozef and Andreas Pluckthun., "In vitro selection and evolution of functional proteins by using ribosome display," Proc. Nat'l. Acad. Sci. USA 94(10):4937-42 (1997)	
202	Haq et al. (1995) "Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic Plants." Science 268:714-716	
203	Haralambiev (1967) "Immunogenicity Studies on a Inactivated IBR Vaccine Administered Into the Nasal Mucosa." Acta Vet Acad Sci Hung 26:215-217	
204	Harrington et al. (1992) "An outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant Center." J. Infect Dis. 165:987-993	
205	HCJ Ertl et al., (1996) "Genetic Immunization" Viral Immunization Vol. 9, No. 1, pp. 1-9.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

206	<b>He et al.</b> , "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," <i>Nucl. Acids Res.</i> 25(24):5132-4 (1997)
207	<b>He et al.</b> (1998) "The Paramyxovirus SV5 Small Hydrophobic (SH) Protein Is Not Essential for Virus Growth in Tissue Culture Cells." <i>Virology</i> 250:30-40
208	<b>Hensel and Lubitz</b> (1997) Vaccination by Aerosols: Modulation of Clearance Mechanism in the Lung." <i>Behring. Inst. Mitt.</i> 98:212-219
209	<b>Hill et al.</b> , "Phage presentation," <i>Mol Microbiol</i> 20(4):685-92 (1996)
210	<b>Hoffman and Banerjee</b> (1997) "An Infectious Clone of Human Parainfluenza Virus Type 3." <i>J Virol.</i> 71:4272-4277
211	<b>Hohol et al.</b> (1996) "Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a phase III Pivotal Trial." <i>Ann. N.Y. Acad. Sci.</i> 778:243-250
212	<b>Holzmann, H. et al.</b> , "Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes," <i>Vaccine</i> 10:345 (1992)
213	<b>Hopkins and Yoder</b> (1986) "Reversion to Virulence of Chicken-Passaged Infectious Bronchitis Vaccine Virus." <i>Avian Dis.</i> 30:221-223
214	<b>Hourvitz et al.</b> (1996) "Reactogenicity and immunogenicity of a new recombinant hepatitis B Vaccine containing Pre S Antigens." <i>J Virol. Hepatitis</i> 3:37-42
215	<b>Hristov and Karadjov</b> (1975) <i>Vet Med Nauki</i> 13:5
216	<b>Huang, Sharon K.S. et al.</b> , "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients," <i>J. Invest. Dermatol.</i> 111:662-7 (1998)
217	<b>Hui, George S.N. et al.</b> , "Dominance of Conserved B-Cell Epitopes of the Plasmodium falciparum Merozoite Surface Protein, MSP1, in Blood-Stage Infections of Naïve Aotus Monkeys," <i>Infect. Immun.</i> 64:1502-1509 (1996)
218	<b>Hulskotte et al.</b> (1998) "Towards an HIV-1 vaccine: lessons from studies in macaque models." <i>Vaccine</i> 16:904-915
219	<b>Hurtado et al.</b> (1996) "Identification of Domains in Canine Parvovirus VP2 Essential for the Assembly of Virus-Like Particles." <i>J. Virol</i> 70:5422-5429
220	<b>Iacono-Connors et al.</b> , <i>Virus Res.</i> 43:125-136 (1996)
221	<b>Irvine, K.R. et al.</b> , "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," <i>Journal of Immunology</i> , 156:238-245 (1996)
222	<b>Jia et al.</b> (1995) "A Novel virant of avian infectious bronchitis virus resulting from recombination among three different strains." <i>Arch Virol</i> 140:259-271
223	<b>Jiang et al.</b> (1999) "Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles." <i>Vaccine</i> 17:1005-1013
224	<b>Jiang et al.</b> , "Subtraction hybridization identified a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," <i>Oncogene</i> 11:2477 (1995)
225	<b>Jiang et al.</b> , "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," <i>Proc. Nat'l. Acad. Sci. USA</i> 93:9160 (1996)
226	<b>Jin et al.</b> (1998) "Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV." <i>Virology</i> 251:206-214

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

227	<b>Johnston, et al. (1997)</b> "Genetic to genomic vaccination" Vol. 15, no. 8 pp 808-809	
228	<b>Kang et al. (1999)</b> "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-like Particles." <i>Biol. Chem</i> 380:353-364	
229	<b>Karandikar et al.,</b> "CTLA-4: A Negative Regulator of Autoimmune Disease," <i>J. Exp. Med.</i> 184:783 (1996)	
230	<b>Keck, Et al. (1988)</b> "In Vivo RNA-RNA Recombination of Coronavirus in Mouse Brain." <i>J. Virol.</i> 62:1810-1813	
231	<b>Keenan et al.,</b> "Lack of Protection following immunisation with <i>H. pylori</i> outer membrane vesicles highlights antigenic differences between <i>H. felis</i> and <i>H. pylori</i> ," <i>FEMS Microbiol Lett.</i> 161:21-7 (1998)	
232	<b>Khavari, (1997)</b> "Therapeutic gene delivery to the skin" <i>Molecular Medicine Today</i> , Dec. 1997: 533538	
233	<b>Kim et al.,</b> "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," <i>J. Immunol.</i> 158:816 (1997)	
234	<b>Kim, et al. (1997)</b> "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883.	
235	<b>Kinney et al. (1997)</b> "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53." <i>Virology</i> 230:300-308	
236	<b>Kinney et al.,</b> "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," <i>J. Virol.</i> 62:4697 (1998)	
237	<b>Kleanthous et al.,</b> "Vaccine development against infection with <i>Helicobacter pylori</i> ," <i>Br. Med. Bull.</i> 54:229-41 (1998)	
238	<b>Klinman et al.,</b> "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon $\gamma$ ," <i>Proc. Nat'l. Acad. Sci. USA</i> 93:2879 (1996)	
239	<b>Klinman, D.M. et al.,</b> "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," <i>Journal of Immunology</i> , 158:3635-3639 (1997)	
240	<b>Kobayashi et al.,</b> "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," <i>J. Exp. Med.</i> 170:827 (1989)	
241	<b>Kobyashi, Yuzuru et al.,</b> "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," <i>Infect. Immun.</i> 44:117 (1984)	
242	<b>Kochel, Tadeusz et al.,</b> "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," <i>Vaccine</i> 15:547-552 (1997)	
243	<b>Kodama et al.,</b> "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," <i>Nature</i> 343:531-535 (1990)	
244	<b>Konishi et al.,</b> "A Highly Attenuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," <i>Virology</i> 190:454 (1992)	
245	<b>Koopman et al.,</b> "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," <i>Curr. Opin. Immunol.</i> 9:80-88 (1997)	
246	<b>Kramer and Fritz,</b> "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," <i>Methods in Enzymol.</i> 154:350-367 (1987)	
247	<b>Kramer et al.</b> "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," <i>Nucl. Acids Res.</i> 16:7207 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	<b>09/247,886</b>
	Filing Date	<b>February 10, 1999</b>
	First Named Inventor	<b>Juha Punnonen</b>
	Group Art Unit	<b>1633</b>
	Examiner Name	<b>S. Chen</b>
	Attorney Docket Number	<b>02-030210US</b>
	Date Submitted	<b>March 25, 2002</b>

248	Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984)	
249	Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984)	
250	Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995)	
251	Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992)	
252	Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement," EMBO J. 11:3237-3244 (1992)	
253	Kuchroo et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707 (1995)	
254	Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods in Enzymol. 154:367-382 (1985)	
255	Kunkel, "The efficiency of oligonucleotide directed mutagenesis" Nucleic acids & Molecular Biology 2: 124-135 (1988)	
256	Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Nat'l. Acad. Sci. USA 82:488-492 (1985)	
257	Lagranderie et al. (1993) "BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route." <i>Tubercle and Lung Disease</i> 74:38-46	
258	Lai et al. (1991) "Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 Virus." <i>Proc. Nat'l Acad. Sci. USA</i> 88:5139-5143	
259	Lanar et al. (1996) "Attenuated Vaccinia Virus-Circumsporozoite Protein Recombinants Confer Protection against Rodent Malaria." <i>Infect Immun</i> 64:1666-1671	
260	Lanciotti et al. (1994) "Molecular evolution and epidemiology of dengue-3 viruses." <i>J Gen Virol</i> 75:65-75	
261	Larsen et al., Long Term acceptance of Skin and Cardiac Allografts After Blocking CD40 and CD28 Pathways," <i>Nature</i> 381: 434 (1996).	
262	Laud et al., Human Immunol. 50:91-102 (1996)	
263	Leary et al., "Active Immunization with Recombinant V Antigen from Yersinia Pestis Protects Mice against Plague," <i>Infect. Immun.</i> 3:2854 (1995)	
264	Lee et al., (1997) "Generation of an Infectious cDNA of a highly cardiovirulent coxsakievirus B3(CVB3m) and comparison to other infectious CVB cDNAs." <i>Virus Res</i> 50:255-235	
265	Lee et al., "Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Factor Gene," <i>J. Virol</i> 72:8430-6 (1998)	
266	Lehrer et al. (1998) "Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis." <i>FEMS Immunol. Med. Microbiol.</i> 21:71-77	
267	Leung et al. (1989) <i>Technique</i> 1(1):11-15	
268	Li et al. (1997) "Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in Escherichia coli. ..." <i>J. Virol</i> 71(4):2988-2995	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

- |     |   |
|-----|---|
| 269 | Li et al., "Cloning and functional characterization of a subunit of the transporter associated with antigen processing," Proc. Natl. Acad. Sci USA 94: 8708-8713 (1997).  |
| 270 | Liao et al. (1990) <i>Gene</i> 107-111  |
| 271 | Liao et al., "STRL22 is a Receptor for the CC Chemokine MIP-3 $\alpha$ ," Biochem. and Biophys. Comms. 236: 212-217 (1997).   |
| 272 | Liblau et al. "Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific autoimmune diseases," Immunol. Today 16:34-38 (1995)  |
| 273 | Liem et al. (1994) <i>Nucleic Acids Res</i> 22(9):1613-1619   |
| 274 | Lieschke et al., "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotech. 15:35 (1997)  |
| 275 | Limbach and Paoletti (1996) "Non-replicating expression vectors: applications in vaccine development and gene therapy." <i>Epidemiol. Infect.</i> 116:241-256   |
| 276 | Lowe et al. (1997) "Human Papillomavirus Typw 2 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like particles Expressed in Yeast." <i>J. Invest Dis</i> 176:1141-1145        |
| 277 | Lowman, Henry B. and Jame A. Wells, "Affinity Maturation of Human Growth Hormone by Monovalent Phage Display," <i>J. Mol. Biol.</i> 234:564-578 (1993)  |
| 278 | Lowman, Henry B. and James A. Wells, "Monovalent Phage Display: A Method for Selecting Variant Proteins from Random Libraries," <i>Methods: A Companion to Methods Enz.</i> 3(3):205-216 (1991)   |
| 279 | Lu, Zhijian et al., "Expression of Thioredoxin Random Peptide Libraries on the Escherichia coli Cell Surface as Functional Fusions to Flagellin: A System Designed for Exploring Protein-Protein Interactions," <i>Bio/Technology</i> 13:366-372 (1995)         |
| 280 | Luytjes et al. (1989) "Amplification, Expression and Packaging of a Foreign Gene by Influenza Virus." <i>Cell</i> 59:1107-1113  |
| 281 | Mandl et al. (1997) "Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr." <i>J. Gen. Virol</i> 78:1049-1057  |
| 282 | Marchetti, Marta et al., "Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant," <i>Vaccine</i> 16:33-7 (1998) |
| 283 | Marusina et al., "Allelic Variation in the Mouse Tap-1 and Tap-2 Transporter Genes," <i>J. Immunol.</i> 158:5251-5256 (1997)  |
| 284 | Mattheakis, Larry C. et al., "An in vitro polysome display system for identifying ligands from very large peptide libraries," Proc. Nat'l. Acad. Sci. USA 91(19):9022-6 (1994)  |
| 285 | McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by "Proteome" Technologies," <i>Helicobacter</i> 3:163-9 (1998)  |
| 286 | McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by Two-Dimensional Gel Electrophoresis, Sequence Analysis, and Serum Profiling," <i>Clin. Diagn. Lab. Immunol.</i> 5:537-42 (1998)             |
| 287 | McCutcheon et al. "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," <i>J. Immunol. Methods</i> 210:149-66 (1997)   |
| 288 | McGregor, Duncan, "Selection of Proteins and Peptides from Libraries Displayed on Filamentous   |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002



	Bacteriophage," Mol Biotechnol. 6(2):155-62 (1996)	
289	Melen et al., "Enzymatic Characterization of Interferon-Induced Antiviral GTPases Murine Mx1 and Human MxA Proteins," J. Biol. Chem. 269: 2009-2015 (1994).	
290	Metz et al. (1996) "Bicistronic and Two-Gene Retroviral Vectors for Using MDR1 as a Selectable Marker and a Therapeutic Gene." <i>Virology</i> 217:230-241	
291	Meulenberg et al. (1998) "An Infectious cDNA Clone Porcine Reproductive and Respiratory Syndrome Virus." <i>Coronaviruses and Arteriviruses</i> 440:199-206	
292	Meulenberg et al. (1998) "Infectious Transcripts from Cloned Genome-Length cDNA of Porcine Reproductive and Respiratory Syndrome Virus." <i>J. Virol.</i> 72:380-387	
293	Meyer et al. (1998) "Bovine herpesvirus type 1 glycoprotein H is essential for penetration and propagation in cell culture." <i>J. Gen. Virol.</i> 79:1983-1987	
294	Mittelholzer et al. (1997) "Generation of cytopathogenic RNA of classical swine fever in persistently infected porcine cell lines." <i>Virus Res</i> 51:125-137	
295	Monaco, "Pathways for the processing and presentation of antigens to T cells," J. Leukocyte Biol. 57:543-57 (1995)	
296	Morita et al. (1987) "Recombinant vaccinia virus LC16m0 or LC1m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus." <i>Vaccine</i> 5:65-70	
297	Mosmann and Coffman, Adv. Immunol. 46:111 (1989)	
298	Moss (1994) "Replicating and Host-Restricted Non-Replicating Vaccinia Virus Vectors for Vaccine Development." <i>Dev. Biol. Stand</i> 82:55-63	
299	Mundt and Vakharia (1996) "Synthetic transcripts of double-stranded Birnavirus genome are infectious." <i>Proc Nat'l Acad. Sci USA</i> 93:11131-11136	
300	N. Miller et al., (1995) "Targeted vectors for gene therapy," FASEB J., 9, pp. 190-199.	
301	Nakamaye and Eckstein, "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," Nucl. Acids Res. 14:9679-9698 (1986)	
302	Nambiar et al., "Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," Science 223:1299-1301 (1984)	
303	Nazerian et al. (1996) "Protection and synergism by Recombinant Fowl Pox Vaccines Expressing Genes from Marek's Disease Virus." <i>Avian Dis.</i> 40:368-376	
304	Nemoto, Naoto et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," FEBS Lett. 414(2):405-8 (1997)	
305	Ness, J. et al., (1999) "DNA shuffling of subgenomic sequences of subtilisin." <i>Nature Biotechnology</i> 17:893-896.	
306	Neurath, A.R. et al., "Monoclonal Antibodies to Hepatitis B Surface Antigen (HBsAg) with Anti-a Specificity Recognize A Synthetic Peptide Analogue (S135-155) with Unmodified Lysine (141)," J. Virol. Methods 9:341-346 (1984)	
307	Ni and Barrett, "Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations," J. Gen. Virol. 76:401 (1995)	
308	Notka et al. (1999) "Construction and Characterization of Recombinant VLPs and Semliki-Forest Virus Live Vectors for Comparative Evaluation in the SHIV Monkey Model." <i>Biol Chem</i> 380:341-352	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

- |     |  |
|-----|--|
| 309 | O'Neil, Karyn T. et al., "Phage display: protein engineering by directed evolution," <i>Curr. Opin. Struct. Biol.</i> 5(4):443-9 (1995)  |
| 310 | Oda Kobe J. Med. Sci. 22:123 (1976)  |
| 311 | Orme (1997) "Progress in the development of new vaccines against tuberculosis," <i>Int. J. Tuberc. Lung Dis</i> 1:95-100   |
| 312 | Ortmann et al., "A Critical Role for Tapasin in the Assembly and Function of Multimeric MHC Class 1-TAP Complexes," <i>Science</i> 277: 1306-1309 (1997).  |
| 313 | Paoletti et al. (1995) "Highly Attenuated Poxvirus: HYVAC, ALVAC and TROVAC," <i>Dev Biol Stand</i> 84:159-163   |
| 314 | Park and RajBhandary (1998) "Tetracycline-Regulated Suppression of Amber Codons in Mammalian Cells," <i>Mol Cell Biol</i> 18:4418-4425   |
| 315 | Parren, Paul W.H.I. et al., "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design," <i>Immunol. Lett.</i> 57:105-112 (1997)                       |
| 316 | Parronchi et al., "IL-4 and IFN (□ and □) Exert Opposite Regulatory Effects on the Development of Cytolytic Potential by Th1 or Th2 Human T Cell Clones," <i>J. Immunol.</i> 149:2977 (1992)           |
| 317 | Paul and Seder, "Lymphocyte Responses and Cytokines," <i>Cell</i> 76:241 (1994)  |
| 318 | Paulusma et al. (1996) "Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene," <i>Science</i> 271:1126-1128   |
| 319 | Pelletier, Joelle N., (2001) "A Rachitt for our toolbox" <i>Nature Biotechnology</i> vol. 19, p. 314-315   |
| 320 | Peng et al. (1998) "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway," <i>Virology</i> 240:147-157  |
| 321 | Penzes et al. (1996) "Replication and Packaging of Coronavirus Infectious Bronchitis Defective RNSa Lacking a Long Open Reading Frame," <i>J. Virol</i> 70:86660-8668                                  |
| 322 | Phizicky, Eric M. et al., "Protein-Protein Interactions: Methods for Detection and Analysis," <i>Microbiol Rev.</i> 59(1):94-123 (1995)  |
| 323 | Pletnev, A.G. et al., Chimeric Tick-Borne Encephalitis and Dengue Type 4 Viruses: Effects of Mutations on Neurovirulence in Mice," <i>J. Virol.</i> 67(8):4956-4963 (1993)                             |
| 324 | Polo et al. (1999) "Stable alphavirus packaging cell lines for Sindbis virus-and Semlike Forest virus-derived vectors," <i>Proc Nat'l Acad. Sci USA</i> 96:4598-4603                                   |
| 325 | Porcelli (1995) <i>Adv. Immunol</i> 59:1   |
| 326 | Powis et al., "Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex," <i>Proc. Nat'l. Acad. Sci. USA</i> 89:1463-1467 (1996) |
| 327 | Premack et al. (1996) <i>Nature Med.</i> 2:1174  |
| 328 | Pryor et al. (1998) "Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins," <i>J. Gen Virol.</i> 79:2631-2639   |
| 329 | Punnonen et al. <i>J. Exp Med.</i> 185:993-1004  |
| 330 | Punnonen et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," <i>Proc. Nat'l. Acad. Sci. USA</i> 90:3730 (1993)                     |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

- |     |  |
|-----|--|
| 331 | Puri et al. (1998) "Complete Nucleotide Sequences Analysis of a Western Pacific Dengue-1 Virus Strain." <i>Virus Genes</i> 17:85-88  |
| 332 | Racke, Michael K. et al., "Cytokine-induced Immune Deviation as a Therapy for Inflammatory Autoimmune Disease," <i>J. Exp. Med.</i> 180:1961-66 (1994)   |
| 333 | Rahden-staron et al. (1991) <i>Biochem &amp; Biophys Res. &amp; Commun.</i> 177(2):597-602   |
| 334 | Raj and Jones (1997) "Growth of infectious bronchitis virus vaccines in oviducts derived from oestrogen-treated chicks and embryos." <i>Vaccine</i> 15:163-168   |
| 335 | Reiser et al., "Cloning and expression of a cDNA for the T-cell-activating protein TAP," <i>Proc. Nat'l. Acad. Sci. USA</i> 85:2255-2259 (1988)  |
| 336 | Roden et al. (1996) "In Vitro Generation and Type Specific Neutralization of a Human Papillomavirus Type 16 Viron Pseudotype." <i>J. Virol.</i> 70:5875-5883   |
| 337 | Roggkamp et al., "Passive Immunity to Infection with Yersinia spp. Mediated by Anti-Recombinant V Antigen is Dependent on Polymorphism of V Antigen," <i>Infect. Immun.</i> 65:446 (1997)                |
| 338 | Roncarolo et al. "Human T- and B-cell functions in SCID-hu mice," <i>Semin. Immunol.</i> 8: 207 (1996).-   |
| 339 | Sagazio et al. (1998) "Antigenic characterization of canine parvovirus strains isolated in Italy." <i>J. Virol. Methods</i> 73:197-200   |
| 340 | Saggio et al. (1995) "CNFT Variants with increased biological potency and receptor selectivity define a functional site of receptor interaction." <i>EMBO Journal</i> 14(13):3045-3054                   |
| 341 | Sakmar and Khorana, "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), <i>Nucl. Acids Res.</i> 14:6361-6372 (1988) |
| 342 | Sanz et al. (1994) "Genetic heterogeneity of the attachment glycoprotein G among A respiratory syncytial virusus." <i>Virus Res</i> 33:203-217   |
| 343 | Saurmann et al. (1990) "Molecular Cloning and Characterization of a German HIV-1 Isolate." <i>AIDS Res. Hum Retroviruses</i> 6:813-823   |
| 345 | Sayers et al. "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide," <i>Nucl. Acids Res.</i> 16:803-814 (1988)    |
| 346 | Sayers et al., "5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis," <i>Nucl. Acids Res.</i> 16:791-802 (1988)  |
| 347 | Schatz, Peter J. et al., "[10] Screening of Peptide Libraries Linked to lac Repressor," <i>Methods Enzymol.</i> 267:171-91 (1996)  |
| 348 | Schmaljohn, A.L. et al., "Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis," <i>Nature</i> 297:70 (1982)  |
| 349 | Schwarz et al. (1957) "Modification of Infectious Bovine Rhinotracheitis (IBR) Virus in Tissue Culture and Development of a Vaccine." <i>Proc Soc Exp. Biol Med.</i> 96:453-458                          |
| 350 | Schwarz et al. (1958) "Propagation and Modification of Infectious Bovine Rhinotracheitis (BR) Virus in Porcine Kidney Tissue Culture." <i>Proc Soc. Exp. Biol. Med</i> 97:680-683                        |
| 351 | Scott, Jamie K. and George P. Smith, "Searching for Peptide Ligands with an Epitope Library," <i>Science</i> 249:386-388 (1990)  |
| 352 | Seliger et al., "TAP off - tumors on," <i>Immunol. Today</i> 18: 292-299 (1997).   |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002



353	Sharma and Graham (1982) "Influence of Material Antibody on Efficacy of Embryo Vaccination with Cell-Associated and Cell-Free Marek's Disease Vaccine." <i>Avian Dis.</i> 26:860-870
354	Sheu et al. (1995) "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B Surface antigen enhances its production in <i>Escherichia coli</i> ." 160(2):179-184
355	Shouval et al. (1994) "Improved immunogenicity in Mice of a mammalian cell-derived recombinant hepatitis B Vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines." <i>Vaccine</i> 12(15):1453-1459
356	Smith, "In Vitro Mutagenesis," <i>Ann. Rev. Genet.</i> 19:423-462 (1985)
357	Sokolic et al. (1996) "A Bicistronic Retrovirus Vector Containing a Picornavirus International Ribosome Entry Site Allows for Correct of X-Linked CGD Selection for MDR1 Expression." <i>Blood</i> 87:42-50
358	Soong et al. (1998) "DNA shuffling as a tool to evolve desired retroviral phenotypes." Abstracts of papers presented at the 1998 meeting on Gene Therapy, p. 228 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, September 23-27, 1998
359	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstract #97, Programs & Abstracts, 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998
360	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstracts of papers presented at the 1998 meeting on Retroviruses, Cold Springs Harbor Laboratory, Cold Spring Harbor, New York, May 26-31, 1998
361	Sosnovtsev et al. (1998) "Cleavage of the Feline Calicivirus Capsid Precursor Is Mediated by a Virus-Encoded Proteinase." <i>J. Virol</i> 72:3051-3059
362	Srinivasan et al. (1987) "Molecular characterization of human immunodeficiency virus from Zaire." <i>Gene</i> 52:71-82
363	Stemmer (1991) "A 20-Minute ethidium bromide/high-salt extraction protocol for plasmid DNA." <i>BioTechniques</i> 10(6): 726
364	Stemmer (1994) <i>Nature</i> 370:389
365	Stemmer et al. (1991) "Expression of antibody Fv Fragments specific for a heavy metal chelate (indium-EDTA) in <i>E. coli</i> ." <i>Journal of Cellular Biotechnology Supplement</i> 0 (15 PART G):217
366	Stemmer et al. (1992) "Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis." <i>BioTechniques</i> 13(2): 214, 216, 218-220
367	Stemmer et al. (1993) "Increased antibody expression from <i>Escherichia coli</i> through wobble-base library mutagenesis by enzymatic inverse PCR." <i>Gene</i> 123(1): 1-7
368	Stemmer et al. (1993) "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR." <i>Biotechniques</i> 14(2): 256-265
369	Stern et al., "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells," <i>Proc. Nat'l. Acad. Sci. USA</i> 87:6808 (1990)
370	Stohwasser et al., "Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon - $\gamma$ -modulated proteasome subunits," <i>Eur. J. Immunol.</i> 27:1182-1187 (1997)
371	Subbarao et al. (1993) Rescue of an Influenza A Virus Wild-type PB2 Gene and a Mutant Derivative Bearing a Site-Specific Temperature-sensitive and Attenuating Mutation." <i>J. Virol.</i> 67:7223-7228

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

Use as many sheets as necessary)



372	<b>Sugimoto et al.</b> (1994) "Characteristics of an attenuated vaccinia virus strain, LC16m0 and It's recombinant virus vaccines." <i>Vaccine</i> 12:675-681	
373	<b>Sugimoto et al.</b> (1995) Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human a-Galactosidase A for Gene Therapy of Febry Disease." <i>Human Gene Ther</i> 6:905-915	
374	<b>Tahara et al.</b> , "IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts," <i>Human Gene Therapy</i> 6:1607 (1995)	
375	<b>Tan et al.</b> , "Characterization of Recombinant Extracellular Domain of Human Interleukin-10 Receptor," <i>J. Biol. Chem.</i> 270:12906 (1995)	
376	<b>Tang et al.</b> , "Vaccination onto bare skin," <i>Nature</i> 388: 729-730 (1997).	
377	<b>Tano et al.</b> (1990) <i>Proc. Nat'l Acad Sci USA</i> 87:686-690	
378	<b>Tartagila et al.</b> (1992) "NYVAC: A Highly Attenuated Strain of Vaccinia Virus." <i>Virology</i> 188:217-232	
379	<b>Tascon, Richard E. et al.</b> , "Vaccination against tuberculosis by DNA injection," <i>Nat. Med.</i> 2:888-92 (1996)	
380	<b>Taylor et al.</b> , "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA," <i>Nucl. Acids Res.</i> 13:8765-8787 (1985)	
381	<b>Taylor et al.</b> , "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA," <i>Nucl. Acids Res.</i> 13:8749-8764 (1985)	
382	<b>Thierfelder et al.</b> "Requirement for Stat4 in interleukin-1-2-mediated responses of natural killer and T cells", <i>Nature</i> 382:171 (1996)	
383	<b>Todd</b> (1974) "Development of Intranasal Vaccination for the Immunization of Cattle Against infectious Bovine Rhinotracheitis." <i>Can. Vet J.</i> 15:257-259	
384	<b>Trudel et al.</b> , "pGATA: A Positive Selection Vector Based on the Toxicity of the Transcription Factor GATA-1 to Bacteria," <i>Biotechniques</i> 20:684-693 (1996).	
385	<b>Tytgat, G.N.</b> , "Review article: practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer," <i>Aliment. Pharmacol. Ther.</i> 12(1):123-8 (1998)	
386	<b>Valle amd Falgout</b> (1998) "Mutagenesis of the NS3 Protease of Dengue Virus Type 2." <i>J. Virol</i> 72:624-632	
387	<b>van Dinten et al.</b> (1997) "An Infectious arterivirus cDNA clone." <i>Proc. Nat'l Acad. Sci USA</i> 94:991-996	
388	<b>VanCott et al.</b> , "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," <i>J. Virol.</i> 71:4319-4330 (1997)	
389	<b>Vassilev et al.</b> (1997) "Authentic and Chimeric Full-length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yeild Infectious Transcrips." <i>J. Virol</i> 71:471-487	
390	<b>Velzing et al.</b> (1999) "Induction of protective immunity against Dengue virus type 2." <i>Vaccine</i> 17:1312-1320	
391	<b>Villinger et al.</b> , "Comparative Sequence Analysis of Cytokine Genes from Human and Nonhuman Primates," <i>J. Immunol.</i> 155:3946-3954 (1995)	
392	<b>Walther et al.</b> (1996) "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting." <i>J. Mol. Med.</i> 74:379-392	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

- |     |  |
|-----|--|
| 393 | Walunas et al., "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405 (1994)  |
| 394 | Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)  |
| 395 | Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil. Trans. R. Soc. Lond. A317:415-423 (1986)  |
| 396 | Wermeille, Joel et al., "The eradication treatments of Helicobacter pylori," Pharm. World Sci. 20:1-17 (1998)  |
| 397 | Whelan et al. (1995) "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones." Proc. Nat'l. Acad. Sci. USA 92:8388-8392   |
| 398 | Whitacre et al., "Treatment of Autoimmune Disease by Oral Tolerance to Autoantigens," Clin. Immunol. Immunopathol. 80: S31-9 (1996).   |
| 399 | Wiertz et al., "SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction," Nature 384: 432 (1996).   |
| 400 | Wiertz et al., "The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class 1 Heavy Chains from the Endoplasmic Reticulum to the Cytosol," Cell 84: 769-779 (1996).                                     |
| 401 | Winther et al. (1998) "Viral-Induced Rhinitis." Am J. Rhinol 12:17-20  |
| 402 | Wisniak et al. (1974) "Hydrogen Solubility in Joboba Oil." JAOCA 51:482-485  |
| 403 | Wloch et al., "The Influence of DNA Sequence on the Immunostimulatory Properties of Plasmid DNA Vectors," Hum. Gene Ther. 9:1439-1447 (1998)   |
| 404 | Woody, Mary Alice et al., "Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model," Vaccine 15(2):133-139 (1997)                                    |
| 405 | Wright et al. (1998) "Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice," Arch Virol 143:1155-1162  |
| 406 | Xiang, Z. et al., "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," Immunity 2:129-135 (1995)                                    |
| 407 | Yanagi et al. (1997) "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee." Proc Nat'l Acad. Sci. USA 94:8738-8743 |
| 408 | Yanagi et al. (1999) "In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone." Proc. Nat'l Acad. Sci USA 96:2291-2295                |
| 409 | Yao et al. (1998) "Generation of Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal Lesions." J. Virol. 72:2647-2654  |
| 410 | Yu et al. (1995) "Functional cDNA Clones of the Human Respiratory Syncytial (RS) Virus. . ." J. Virol 69:2412-2419   |
| 420 | Zamvil, Scott S. and Lawrence Steinman, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Ann. Rev. Immunol. 8:579-621 (1990)   |
| 421 | Zhong et al. (1998) "Identification and Characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," J. Virol. 72:9365-9369      |
| 422 | Zhong, Weimin et al., "Therapeutic passive vaccination against chronic Lyme disease in mice," Proc. Nat'l. Acad. Sci. USA 94:12533-12538 (1997)  |
| 423 | Zoller and Smith, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and  |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

general procedure for the production of point mutations in any fragment of DNA," Nucl. Acids res. 10:6487-6500 (1982)

- |     |  |
|-----|--|
| 424 | Zoller and Smith, "Oligonucleotide-Directed Mutagenesis: A Simple Method using Two Oligonucleotide Primers and a Single-Stranded DNA Template," Methods in Enzymol. 154:329-350 (1987) |
| 425 | Zoller and Smith, "Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors," Methods in Enzymol. 100:468-500 (1983)  |
| 426 | Zou et al. (1995) "Structure-function analysis of the p35 subunit of mouse interleukin 12." J. Bio. Chem. 270(11):5864-5871  |
| 427 | Zuschek et al. (1961) "Immunogenicity of 2 Infectious Bovine Rhinotracheitis Vaccines." J. Am. Vet. Med. Assoc. 139:236-237  |
| 428 | Zygraich et al. (1974) "In Vivo and In Vitro Properties of a Temperature Sensitive Mutant of Infectious Bovine Rhinotracheitis Virus." Res. Vet. Sci. 16:328-335                       |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.